This content is machine translated 57th ASH Meeting in Orlando New field of application for rituximab The ASH Congress was held last year in Orlando. This time, one of the topics was the efficacy of rituximab in adult patients with B-precursor acute lymphoblastic leukemia (ALL). Up…
View Post 3 min This content is machine translated News from the ASH Congress on Nivolumab High response rates even in pretreated Hodgkin’s lymphomas Preclinical studies show that Sternberg-Reed cells, characteristic of classical Hodgkin lymphoma, use the PD-1 pathway to evade immunodetection. Therefore, immune checkpoint inhibitors such as nivolumab, which binds to the PD-1…
View Post 4 min This content is machine translated 2014 Joint ACTRIMS-ECTRIMS Meeting Prizes for promising research in the field of multiple sclerosis At the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston (September 10-13, 2014), the GMSI Award (Grant for Multiple Sclerosis Innovation) was presented to the winners for the second time. The goal…
